Supply Factors Affecting Demand for Health Services

Buying healthcare isn’t like buying bananas. When you buy bananas, you decide how many you want, which bunch looks best, and whether the price is right. You are the “sovereign consumer.” But when was the last time you confidently decided you needed a specific diagnostic test, argued with a surgeon about the brand of scalpel, or picked a prescription drug based on your own research? It almost never happens. In the unique and complex world of healthcare, our “demand” is often shaped, guided, and sometimes even *created* by the supply side: the very doctors, pharmaceutical companies, and insurers we rely on for help.

This creates a fascinating economic puzzle. If the seller is also the person advising the buyer on what to buy, how do we know the advice is perfect? This is where the market for health services diverges dramatically from any other market. Let’s explore the powerful supply-side factors that influence your demand for health.

The curious case of the healthcare market 🔗

In a typical market, the consumer holds the power. This is called consumer sovereignty. If you don’t like a product or its price, you don’t buy it. Producers must compete for your money by offering better quality or lower prices. In healthcare, this model is turned on its head. The “consumer” (the patient) often lacks the specialized knowledge to make an informed decision. You can’t just “shop around” for the best price on heart surgery while you’re having a heart attack.

This power vacuum is filled by three main “third parties” on the supply side:

• Physicians: They act as your expert agent, diagnosing your problem and prescribing a solution.
• Pharmaceutical Companies: They create the treatments (drugs) that physicians prescribe.
• Insurers: They manage the payment, removing the immediate sting of the price from both you and the doctor.

Because of this structure, the patient is often not the primary decision-maker. The demand for health services is heavily influenced, and in some cases determined, by these suppliers. This can lead to significant economic distortions, starting with the person you trust the most: your doctor.

Your doctor as the decision-maker (and the problem of SID) 🔗

In an ideal world, your doctor acts as your perfect agent. They have years of training and experience, and their only goal is to use their knowledge to restore your health in the most effective and efficient way possible. However, the real world is complicated by a powerful economic concept: information asymmetry.

What is information asymmetry? 🔗

Information asymmetry simply means one party in a transaction knows vastly more than the other. When your car makes a funny noise, your mechanic knows more than you. When you have a persistent cough, your doctor knows infinitely more about its potential causes-from a common cold to a serious lung condition-than you do. You cannot possibly have the knowledge to question their diagnosis or treatment plan effectively.

This information gap forces you to trust the doctor to act in your best interest. But what happens when the doctor’s best interests don’t perfectly align with yours? This is where the market gets tricky.

Introducing supplier-induced demand (SID) 🔗

Supplier-Induced Demand (SID) is a situation where a supplier (the doctor) uses their superior information to encourage a consumer (the patient) to consume more of their service than is medically necessary. It’s not necessarily malicious. It can be subtle. It’s the “just to be safe” CT scan for a headache that has a 99.9% chance of being benign, or the recommendation for a slightly more aggressive (and expensive) treatment plan when a simpler one would also work.

A classic economic theory known as the “target income hypothesis” suggests this can be a response to market forces. If physician density increases in an area-meaning more doctors are competing for the same pool of patients-they may, consciously or not, adjust their treatment recommendations to ensure they meet their own income expectations. This can involve ordering more tests, scheduling more follow-up visits, or recommending elective procedures more readily.

The economic problem with SID 🔗

The problem with SID is that it leads to a “welfare loss.” This is the economic term for waste. Society’s resources (highly trained doctors, expensive scanning machines, hospital beds) are used to provide care that has very little or no marginal benefit to the patient’s actual health. That money and time could have been spent on patients who *genuinely* needed the care, or on other public goods like education or infrastructure. It’s a misallocation of resources driven directly by the information gap between supplier and consumer.

The pill push: How pharmaceutical companies shape demand 🔗

The second major supplier influencing demand is the pharmaceutical industry. These companies wield enormous market power, and for good reason: they create life-saving drugs. But that power comes with economic side effects.

The high price of innovation (and marketing) 🔗

Developing a new drug is incredibly expensive and risky. It can take over a decade and cost billions of dollars, with most potential drugs failing in trials. To incentivize this innovation, governments grant patents, which give the company a temporary monopoly on their new drug. During this period, they can charge high prices to recoup their research and development (R&D) costs.

However, a massive chunk of their budget also goes to promotional expenses. This isn’t just TV commercials. A significant portion is spent marketing directly to physicians through medical sales representatives, sponsoring conferences, and providing samples. In the fast-growing Indian pharmaceutical market, for example, this physician-focused marketing is a key competitive strategy.

Unhealthy ties and created demand 🔗

This intense marketing can create another form of supplier-induced demand. A doctor may be influenced to prescribe a new, expensive, branded drug when an older, cheaper, and equally effective generic drug is available. They might be persuaded that a new “wonder drug” is necessary for a mild condition that might resolve on its own. The information asymmetry here is two-fold: the patient doesn’t know the cheaper alternative exists, and even the doctor may be relying on biased information provided by the drug company’s marketing team.

When patients end up consuming unnecessary or overly expensive drugs, it creates another significant welfare loss. The patient (or their insurer) pays a high price for a benefit that is minimal or non-existent, diverting funds that could be used for more pressing health needs.

The insurance puzzle: Protection, prices, and ‘moral hazard’ 🔗

The third and perhaps most complex supplier factor is health insurance. On the surface, insurance is a wonderful thing. It’s a pooling arrangement where everyone pays a small amount (a premium) to ensure that if someone faces a catastrophic, unpredictable medical expense, they won’t be financially ruined. It turns a large, uncertain risk into a small, predictable cost.

However, conventional insurance theory points to a major side effect that distorts demand: moral hazard.

What exactly is moral hazard? 🔗

Moral hazard is the idea that people behave differently when they are protected from risk. If you have comprehensive car insurance, you might be slightly less careful about where you park or more willing to drive in bad weather. You don’t bear the full cost of your actions, so your incentives change.

In healthcare, this manifests in a specific way. When you have good health insurance, the out-of-pocket cost of a doctor’s visit or a medical test is very low, perhaps just a small co-payment or even zero. The price signal is broken. You no longer have to ask, “Is this $500 MRI *really* worth $500 to me?” Instead, you ask, “Is this $20 co-pay worth it?” The answer is almost always yes.

The high cost of ‘free’ healthcare 🔗

This leads to the over-consumption of healthcare. Consumers (patients) are incentivized to demand services where the marginal benefit is far lower than the marginal cost. You might go to the doctor for a minor cold you would have otherwise treated at home. You might agree to that “just to be safe” scan. This isn’t your “fault”-it’s a rational response to the incentives your insurance policy creates.

This results in a massive welfare loss. The system becomes flooded with demand for low-value care. This drives up the total cost of healthcare for everyone, which in turn forces insurers to raise premiums for the following year. As policymakers in India and around the world grapple with rising healthcare costs, managing the moral hazard created by insurance-without penalizing people who are genuinely sick-remains one of the biggest challenges in health economics.

Ultimately, the “demand” for healthcare is a complex negotiation between the patient’s needs, the physician’s expertise and incentives, the pharmaceutical industry’s influence, and the distorted price signals created by insurance. You aren’t just a consumer; you are a participant in a complex system where the suppliers often hold all the cards.

What do you think? Have you ever felt you were being “sold” a medical test or prescription you weren’t sure you needed? How can we better align the incentives of doctors and insurers with the best long-term health interests of patients?

References

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567746/
2. https://www.ibef.org/industry/pharmaceutical-india
3. https://www.imf.org/external/pubs/ft/fandd/2010/06/basics.htm